Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from PDS Biotechnology ( (PDSB) ).
On September 18, 2025, PDS Biotechnology announced a significant achievement in its VERSATILE-002 Phase 2 clinical trial for head and neck cancer patients with low PD-L1 expression. The trial showed a median overall survival of 29.5 months for the cohort treated with PDS0101 and Keytruda, compared to 10.8 months with Keytruda alone and 12.3 months with Keytruda plus chemotherapy. This result suggests that PDS0101 may significantly improve survival for a difficult-to-treat patient population, potentially eliminating the need for chemotherapy.
The most recent analyst rating on (PDSB) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on PDS Biotechnology stock, see the PDSB Stock Forecast page.
Spark’s Take on PDSB Stock
According to Spark, TipRanks’ AI Analyst, PDSB is a Neutral.
PDSB’s overall score reflects the typical high-risk, high-reward nature of early-stage biotech firms. The company’s strong clinical progress and cash position are significant positives, but financial sustainability and valuation concerns due to ongoing losses and reliance on external funding temper the outlook. Technical indicators suggest some positive momentum, albeit with caution.
To see Spark’s full report on PDSB stock, click here.
More about PDS Biotechnology
PDS Biotechnology is a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers. The company is advancing its lead program in advanced HPV16-positive head and neck squamous cell cancers, with its investigational immunotherapy PDS0101 being developed in combination with standard-of-care immune checkpoint inhibitors.
Average Trading Volume: 481,959
Technical Sentiment Signal: Sell
Current Market Cap: $54.08M
Find detailed analytics on PDSB stock on TipRanks’ Stock Analysis page.